CYTOKINETICS INC

Callos Andrew’s latest insider moves reveal Cytokinetics’ confidence ahead of MYQORZO data—new RSUs and options, a small sale, and a clear long‑term alignment with investors.

Insightful look at Cytokinetics insider sales: Andrew’s routine sell‑to‑cover, market sentiment, and what it means for investors.

Callos Andrew’s back‑to‑back buy‑sell of Cytokinetics shares signals strategic rebalancing, hinting insider confidence amid upcoming MYQORZO milestones.